Vaccine hypersensitivity - Update and overview

Swiss Medical Weekly

Volumn 140, Issue 17-18, 2010, Pages 238-246

  Fritsche, Philipp J ^a   Helbling, Arthur ^b   Ballmer Weber, Barbara K ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antibiotics; Delayed type vaccine allergy; Egg protein; Gelatine; Immediate type vaccine allergy; Macrophagic myofasciitis; Revaccination; Toxoids; Vaccine allergy; Vaccine induced adverse events

Indexed keywords

ALLERGEN; ALUMINUM SALT; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIBIOTIC AGENT; CHICKENPOX VACCINE; CHLORTETRACYCLINE; CHOLERA VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA POLIOMYELITIS TETANUS VACCINE; ECEPUR N; EGG PROTEIN; ENCEPUR N; ENCEPUR N KINDER; FSME IMMUN CC; FSME IMMUN JUNIOR; GELATIN; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HERPES SIMPLEX VACCINE; IMMUNOGLOBULIN E; INFLUENZA VACCINE; INFLUVAC PLUS; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MUMPS VACCINE; NEOMYCIN; OVALBUMIN; PENTAVAC; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIORIX; POLYMYXIN B; RABIES VACCINE; RECOMBINANT HEPATITIS B VACCINE; REVAXIS; RUBELLA VACCINE; STAMARIL; TBE AND RABIPUR; TETANUS TOXOID; TETRAVAC; TICK BORNE ENCEPHALITIS VACCINE; TOLLWUT IMPFSTOFF MERIEUX; TYPHOID VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE; ALUMINUM DERIVATIVE; ANTIINFECTIVE AGENT; FUNGAL PROTEIN; PRESERVATIVE; THIOMERSAL; TOXOID;

ACCURACY; ALGORITHM; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BRONCHOSPASM; CONTACT DERMATITIS; DIAGNOSTIC PROCEDURE; DRUG FORMULATION; DRUG HYPERSENSITIVITY; ECZEMA; FAINTNESS; FLUSHING; HUMAN; HYPOTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; INFLAMMATION; INJECTION SITE REACTION; INJECTION SITE SWELLING; MEDICAL DECISION MAKING; MICROORGANISM; REVACCINATION; REVIEW; RHINOCONJUNCTIVITIS; SHOCK; URTICARIA; VACCINATION; VERTIGO; CHEMICALLY INDUCED; DELAYED HYPERSENSITIVITY; DRUG SURVEILLANCE PROGRAM; RISK FACTOR;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; ALUMINUM COMPOUNDS; ANTI-BACTERIAL AGENTS; DRUG HYPERSENSITIVITY; EGG PROTEINS; FUNGAL PROTEINS; GELATIN; HUMANS; HYPERSENSITIVITY, DELAYED; HYPERSENSITIVITY, IMMEDIATE; PRESERVATIVES, PHARMACEUTICAL; RISK FACTORS; THIMEROSAL; TOXOIDS; VACCINES;

EID: 77951734489     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Measles: progress towards global control and regional elimination, 1998-1999. Weekly Epidemiological Record. 1999;74:429-434
2. CDC. Progress toward interruption of wild poliovirus transmission - worldwide, 2008. MMWR. 2009;58:308-312
3. World Health Organization. Une Pléthore de vaccins haute technologie - génétiques, comestibles, en sucre vitreux et autres. CVI Forum. 1999;5-24.
4. Zimmermann HP, Pfiffner D, Bourquin C, Matter H. Epidémiologie des maladies évitables par la vaccination. Rev Méd Suisse Romande 1998;118:301-308 (Pubitemid 28201050)
5. Davies P, Chapman S, Leask J. Antivaccination activists on the world wide web. Arch Dis Childhood 2002;87:22-25 (Pubitemid 34753767)
6. www.aegis.ch
7. Lawrence GL, Boyd I, McIntyre PB, Isaacs D. Annual report: surveillance of adverse events following immunisation in Australia, 2004. Commun Dis Intell. 2005;29(3):248-262
8. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for Safety after Immunization: Vaccine Adverse Event Reporting System (VAERS), United States, 1991-2001. MMWR 2003/52 (ss01); 1-24.
9. Maas NAT van der, Phaff TAJ, Wesselo C, Vermeer-de Bondt PE. Adverse Events Following Immunisation under the National Vaccination Programme of the Netherlands. Number XIII - reports in 2006.RIVM rapport 240071004.
10. Decker MD, Edwards KM. Acellular pertussis vaccines. Pediatric Clinics of North America 2000;47:309-355
11. Wharton M, Bisgard KM, Murphy TV. Use of diphtheria toxoid - tetanus toxoid - acellular pertussis vaccine as a five-dose series. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2000;49(Suppl. RR-13):1-8.
12. Jacobs RL, Lowe RS, Lanier BQ. Adverse reactions to tetanustoxoid. JAMA. 1982;247:40-42
13. Gardner P. Issues related to the decennial tetanus-diphtheria toxoid booster recommendations in adults. Infect Dis Clin North Am. 2001;15:143-153, ix-x. (Pubitemid 32268118)
14. Andrews RM, Kempe AE, Herceg A. Vaccinating children with a history of serious reactions after vaccination or of egg allergy. Med Austr. 1998;168:491-494 (Pubitemid 28242906)
15. Gold M, Goodwin H, Botham S, Burgess M, Kempe A. Revaccination of 421 children with a past history of an adverse reaction in a special immunization service. Arch Dis Child. 2000;83:128-131 (Pubitemid 30670421)
16. KobayashiRH.Vaccination.Immunol Allergy Clin N Amer.1995;15:553-566
17. Poley GE, Slater JE. Drug and vaccine allergy. Immunol Allergy Clin N Amer. 1999;19:409-422
18. Ada G. Vaccines and vaccination. N Engl J Med. 2001;345(14):1042-1053
19. Patja A, Paunio M, Kinnunen E, Juntila O, Hovi T, Peltola H. Risk of Guillain-Barre syndrome after measles-mumps-rubella vaccination. J Pediatr. 2001;138:250-254 (Pubitemid 32156442)
20. Tuttle J, Chen R, Rantala H, Cherry JD, Rhodes PH, Hadler S. The risk of Guillain-Barré syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States. Am J Public Health 1997;87:2045-2048 (Pubitemid 28055931)
21. Eaton L. New research on autism and measles "proves nothing". BMJ. 2002;324:315.
22. Zipp F, Weil JG, Einhäupl KM. No increase in demyelinating diseases after hepatitis B vaccination. Nature Medicine. 1999;5:964-965
23. Confavreux C, Suissa S, Saddier P, Bourdès V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med. 2001;344:319-326 (Pubitemid 32107639)
24. Davis RL, Kramarz P, Bohlke K, Benson P, Thompson RS, Mullooly J, et al. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. Arch Pediatr Adolesc Med. 2001;155:354-359 (Pubitemid 32199182)
25. Taylor B, Miller E, Farrington CP, Petropoulos MC, Favot-Mayaud I, Li J, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for causal association. Lancet. 1999;353:2026-2029
26. Mäkelä KM, Nuorti JP, Peltola H. Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics. 2002;110:957-963
27. Kuehni CE, Brooke AM, Davis A, Silverman M. Vaccination as risk factors for wheezing disorders. Lancet. 2001;358:1186.
28. Fleming PJ, Blair PS, Platt MW, Tripp J, Smith IJ, Golding J. The UK accelerated immunisation programme and sudden unexpected death in infancy: case-control study. BMJ. 2001;322:822.
29. Zent O, Arras-Reiter C, Broeker M, Hennig R. Immediate allergic reactions after vaccinations - a postmarketing surveillance review. Eur J Pedatr 2002;161(1):21-25 (Pubitemid 34031271)
30. Bohlke K, Robert L. Risk of Anaphylaxis After Vaccination of Children and Adolescents. Pediatrics. 2003;112:815-820 (Pubitemid 37248689)
31. Bastyr EJ. Latex allergen allergic reactions. Diabetes Care. 1996;19:546.
32. MacCracken J, Stenger P, Jackson T. Latex allergy in diabetic patients: a call for latex-free insulin tops. Diabetes Care. 1996;19:184.
33. Ponvert C, Scheinmann P, Karila C, Bakonde VB, Le Bourgeois M, de Blic J. L'allergie aux vaccines associés chez l'ènfant: une étude de 30 cas fondée sur les tests cutanés à lecture immédiate, semi-retardée et retardée, sur les dosages des anticorps spécifiques et sur les injections e rappel. Rev Fr Allergol Immunol Clin. 2001;41:701-711 (Pubitemid 34024151)
34. Facktor MA, Bernstein RA, Firemann P. Hypersensitivity to tetanus toxoid. J Allergy Clin Immunol. 1973;52:1-12.
35. Cox NH, Moss C, Forsyth A. Allergy to non-toxoid constituents of vaccines and implications for patch testing. Contact dermatitis. 1988;18:143-146 (Pubitemid 18077540)
36. Vogt T, Landthaler M, Stolz W. Generalized eczema in a 18-month-old boy due to penoxyethanol in DTP vaccine. Contact Dermatitis. 1998;38:50-51 (Pubitemid 28059746)
37. Ghadially R, Ramsay CA. Gentamicin: systemic exposure to a contact allergen. J Am Acad Dermatol. 1988;19:428-430
38. Sutter RW. Adverse reactions to tetanus toxoid. JAMA. 1994;271(20):1629.
39. Rennels MB, Deloria MA, Pichichero ME, Losonsky GA, Englund JA, Meade BD, et al. Extensive swelling after booster doses of acellular pertussis-tetanus- diphtheria vaccines. Pediadrics. 2000;105:e12.
40. Blennow M, Granstrom M. Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants. Pediatrics. 1989;84:62-67 (Pubitemid 19168038)
41. Tariq SM, Matthews SM, Hakim EA, Arshad SH. Egg allergy in infancy predicts respiratory allergic disease by 4 years of age. Pediatr allergy Immunol Aug. 2000;11:162-167
42. Zeiger RS. Current issues with influenza vaccination in egg allergy. J Allergy Clin Immunol. 2002;110:834-840
43. Baxter DN. Measles immunization in children with a history of egg allergy. Vaccine. 1996;14:131-134 (Pubitemid 26074239)
44. Beck S, Williams LW, Shirrel MA, Burks AW. Egg hypersensitivity and measles-mumps-rubella vaccine administration. Pediadrics. 1991;88:913-917
45. Fasano MB, Wood RA, Cooke SK, Sampson HA. Egg hypersensitivity and adverse reactions to measles, mumps and rubella vaccine. J Pediatr. 1992;120:878-881
46. Freigang B, Jadavji TP, Freigang DW. Lack of adverse reactions to measles, mumps, and rubella vaccine in egg-allergic children. Ann Allergy. 1994;73:486-488
47. James JM, Burks, AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med. 1995;232:1262-1266
48. James JM, Zeiger RS, Lester MR, Fasano MB, Gern JE, Mansfield LE, et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr. 1998;133(5):624-628 (Pubitemid 28521210)
49. Murphy KR, Strunk RC. Safe administration of influenza vaccine in asthmatic children hypersensitive to egg protein. J Pediatr. 1985;106:931-933
50. Anolik R, Spiegel W, Posner M, Jakabovics E. Influenza vaccine testing in egg sensitive patients. Ann Allergy. 1992;68(1):69.
51. Pool V, Braun MM, Kelso JM, Mootrey G, Chen RT, Yunginger JW, et al; VAERS Team. US Vaccine Adverse Event Reporting System. IgE sensitization to gelatin: the probable role of gelatin-containing diphtheria-tetanus-acellular pertussis (DTaP) vaccines. Pediatrics. 2002;110(6):e71.
52. Zent O, Hennig R. Post-marketing surveillance of immediate allergic reactions: polygeline-based versus polygeline-free pediatric TBE vaccine. Vaccine. 2004;23(5):579-584 (Pubitemid 39473186)
53. Kelso JM, Jones RT, Yunginger JW. Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin. 1993;91(4):867-872
54. Patja A, Mäkinen-Kiljunen S, Davidkin I, Paunio M, Peltola H. Allergic reactions to measles-mumps-rubella vaccination. Pediatrics. 2001;107(2):E27.
55. Nakayama T, Aizawa C, Kuno-Sakai H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. J Allergy Clin Immunol. 1999;103(2 Pt 1):321-325 (Pubitemid 29095839)
56. Sakaguchi M, Inouye S. IgE sensitization to gelatin: the probable role of gelatin-containing diphtheria-tetanus-acellular pertussis (DTaP) vaccines. Vaccine. 2000;18(19):2055-2058 (Pubitemid 30114351)
57. ENGERIX B (GlaxoSmithKline) Hepatitis B vaccine (recombinant). GlaxoSmithKline; 2004. Vaccine package insert.
58. TWINRIX (GlaxoSmithKline) hepatitis A inactivated & hepatitis B (recombinant).GlaxoSmithKline; 2003. Vaccine package.
59. DiMiceli L, Pool V, Kelso JM, Shadomy SV, Iskander J, V.A.E.R.S. Team. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS).Vaccine. 2006;24(6):703-707
60. Neal A, Halsey MD. The human papillomavirus vaccine and risk of anaphylaxis. CMAJ. 2008;179(7):678.
61. Arzneimittel-Kompendium der Schweiz, Documed AG, Basel, Switzerland 2008.
62. Kwittken PL, Rosen S, Sweinberg SK. MMR vaccine and neomycin allergy. Am J Dis Child. 1993;147:128-129
63. Watson JC, Peter G. General immune practices. In: Plotkin SA, Orenstein WA, editors Vaccines 3rd ed Philadelphia: WB Saunders; 1999. p. 47-73.
64. Crockett RE, Lockey RF. Vaccine hypersensitivity. Immunol Allergy Clin North Am. 2001;21:707-743
65. MMWR 1998;47:34-35
66. Pradad R. Anaphylactic shock due to streptomycin sulphate, J Ind Med Assoc. 1984;82:254-255 (Pubitemid 15117443)
67. Romano A, Viola M, Di Fonso M, Rosaria Perrone M, Gaeta F, Andriolo M. Aaphylaxis to streptomycin. Allergy. 2002;57(11):1087-1088
68. Paniagua MJ, Garcia-Ortega P, Tella R, Gaig P, Richart C. Systemic contact dermatitis to gentamicin. Allergy. 2002;57(11):1086-1087
69. Katsarou-Katsari A, Armenaka M, Katsenis K, Papageorgiou M, Katsambas A, Bareltzides A. Contact allergens in patients with leg ulcers. J Eur Acad Dermatol Venerol. 1998;11(1):9-12. (Pubitemid 28383608)
70. Connolly M, Mc Adoo J, Bourke JF. Gentamicin-induced anaphylaxis. Ir J Med Sci. 2007;176(4):317-318
71. Schulze S, Wollina U. Gentamicin-induced anaphylaxis. Allergy. 2003;58(1):88-89
72. Hillen U, Geier J, Goos M. Contact allergies in patients with eczema of the external ear canal. Results of the Information Network of Dermatological Clinis and the German Contact Allergy Group. Hautarzt. 200;51(4):239-243
73. Eedy DJ, McMillan JC, Bingham EA. Anaphylactic reactions to topical antibiotic combinations. Postgrad Med J. 1990;66(780):858-859
74. Muñoz Bellido FJ, Moyano JC, Alvarez M, Juan JL, Bellido J. Contact sensitivity to gentamicin with tolerance of systemic exposure. Allergy. 1996;51(10):758-759 (Pubitemid 26343816)
75. Zheng W, Dreskin SC. Thimerosal in influenza vaccine: an immediate hypersensitivity reaction. Ann Allergy Asthma Immunol. 2007;99(6):574-575 (Pubitemid 350308761)
76. http://www.bag.admin.ch/
77. Audicana MT, Muñoz D, del Pozo MD, Fernández E, Gastaminza G, Fernández de Corres L. Allergic contact dermatitis from mercury antiseptics and derivatives: study protocol of tolerance to intramuscular injections of thimerosal. Am J Contact Dermat. 2002;13:3-9.
78. Cox NH, Forsyth A. Thimerosal allergy and vaccination reactions. Contact Dermatitis. 1988;18:229-233
79. Wattanakrai P, Rajatanavin N. Thimerosal allergy and clinical relevance in Thailand. J Med Assoc Thai. 2007;90(9):1775-1779 (Pubitemid 350057135)
80. Statement on thiomersal, WHO, 2006
81. DeStefano F. Vaccines and autism: evidence does not support a causal association. Clin Pharmacol Ther. 2007;82(6):756-759 (Pubitemid 350114826)
82. Offit P, Jew R. Addressing parents' concerns: do vaccines contain harmful preservatives, adjuvants, additivese, or residuals? Pediatrics. 2003;112 (6 Pt 1):1394-1397
83. García-Patos V, Pujol RM, Alomar A, Cisteró A, Curell R, Fernández-Figueras MT, et al. Persistent subcoutaneous nodules in patients hyposensitized with aluminum-containing allergen extracts. Allergy. 1985;40:368-372
84. Pricilla Costa Ferreira, Kamila de Almeida Piai, Angela Maria Magossa Takayanagui, Susana Inés Segura Muñoz. Aluminum as a risk factor for Alzheimer's disease. Rev Lat Am Enfermagem. 2008;16(1):151-157
85. Rondeau V, Jacqmin-Gadda H, Commenges D, Helmer C, Dartigues JF. Aluminum and silica in drinking water and the risk of Alzheimer's disease or cognitive decline: findings from 15-year follow-up of the PAQUID cohort. Am J Epidemiol. 2009;169(4):489-496
86. Weintraub R, Hams G, Meerkin M, Rosenberg AR. High aluminum content of infant milk formulas. Arch Dis Child. 1986;61:914-916 (Pubitemid 16013869)
87. Mandić ML, Grgić J, Grgić Z, Seruga M, Hasenay D. Aluminum levels in human milk. Sci Total Environ. 1995;170:165-170
88. Gherardi RK. Lessons from macrophagic myofasciitis: towards definition of a vaccine adjuvant-related syndrome. Rev Nerol (Paris). 2003;159(2):162-164
89. Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, et al. Macrophagic myofasciitis lesions assess longterm persistence of vaccine-derived aluminum hydroxide in muscle. Brain. 2001;125 (Pt 9):1821-1831 (Pubitemid 32845443)
90. Global advisory committee on Vaccine Safety. 3-4 December 2003.
91. Cody CL. Baraff LJ, Cherry JD. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics. 1981;68:650-660
92. Pollock TM, Morris J. A 7-year survey of disorders attributed to vaccination in North West Thames region. Lancet. 1983;I:753-757 (Pubitemid 13161325)
93. Smith RE, Wolnitski C. Allergic reactions to tetanus, diphtheria, influenza, and poliomyelitis immunization. Ann Allergy. 1962;20:809-813
94. Steele RH, Limaye S, Cleland B, Chow J, Suranyi MG. Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin. Nephrology. (Carlton) 2005;10:317-320
95. Coors EA, Seybold H, Merk HF, Mahler V. Polysorbate 80 in medical products and nonimmunological anaphylactoid reactions. Ann Allergy Asthma Immunol. 2005;95(6):593-599 (Pubitemid 43010488)
96. Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful longterm therapy. Allergy Asthma Proc. 2007 May-Jun; 28 (3):313-319
97. Vaidya SJ, Seydel C, Patel SR, Ortin M. Anaphylactic reaction to liposomal amphotericin B. Ann Pharmacother. 2002;36(9):1480-1481
98. Cesaro S, Calore E, Messina C, Zanesco I. Allergic reaction to the liposomal component of liosomal amphotericin B. Support Care Center. 1999;7(4):284-286 (Pubitemid 29302638)
99. Kudoh O, Warabi K, Yamaguchi K, Ichinose M, Iizuka T, Inada E. A case of anaphylactic shock in an elderly man following protamine sulfate administration during emergent off-pump coronary artery bypass grafting. Masui. 2006;55(5):605-610 (Pubitemid 43762727)
100. Raap U, Liekenbröcker T, Kapp A, Wedi B. Delayed-type hypersensitivity to protamine as a complication of insulin therapy. Contact dermatitis. 2005;53(1):57-58 (Pubitemid 40977225)
101. Hakala T, Suojaranta-Ylinen R. Fatal anaphylactic reaction to protamine after Femoropoplital by-pass surgery. Ann Chir Gynaecol. 2000;89(2):150-152 (Pubitemid 30646912)
102. Porsche R, Brenner ZR. Allergy to protamine sulfate. Heart Lung. 1999;28(6):418-428
103. Kaminska R, Mörtenhumer M. Allergic contact dermatitis from phenolsulfonphthalein in chlorhexidin solution. Contact dermatitis. 2007;56(6):358-360 (Pubitemid 46934342)
104. Wood RA, Berger M, Dreskin SC, Setse Rosanna, Engler RJM, Cornelia L, et al. An Algorithm for Treatment of Patients With Hypersensitivity Reactions After Vaccines. Pediatrics 2008;122(3):e771-7.
105. American Academy of Pediatrics. Active immunization. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red Book: 2006 Report of the Committee on Infectious Diseases.27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:446-448
106. Lavi S, Zimmerman B, Koren G, Gold R. Administration of measles, mumps and rubella virus vaccine (live) to egg allergic children. J Am Med Assn. 1990;263:269-271 (Pubitemid 20025982)
107. Erlewyn-Lajeunesse M, Brathwaite N, Lucas JSA, Warner JO. Clinical Review, Recommendations for the administration of influenza vaccine in children allergic to egg. BMJ. 2009;339:b3680.
108. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001. MMWR Morbid Mortal Wkly Rep. 2003;23:589-603.
109. Aurelian L, Ono F, Burnett J. Herpes simplex virus (HSV)-associated erythema multiforme (HAEM): a viral, disease with an autoimmune component. Dermatol Online J. 2003;9:1. (Pubitemid 38888667)
110. Huff JC, Weston WL, Tonnesen MG. Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol. 1983;8:763-775
111. Sakaguchi M, Nakayama T, Fujita H, Toda M, Inouye S. Minimum estimated incidence in Japan of anaphylaxis to live virus vaccines including gelatin. Vaccine. 2000;19(4-5):431-436
112. Shelley WB, Talanin N, Shelley ED. Polsorbate 80 hypersensitivity. Lancet. 1995;345:1312-3.144.
113. Bastyr EJ. Latex allergen allergic reactions. Diabetes care. 1996;19:546.
114. MacCracken J, Stenger P, Jackson T. Latex allergy in diabetic patients: a call for latex-free insulin tops. Diabetes Care. 1996;19:546.
115. Georgitis JW, Fasanao MB. Allergenic components of vaccines and avoidance of vaccination-related adverse events. Curr allergy Rep. 2001;1(1):11-17
116. Herman JJ, Radin R, Schneiderman R. Allergic reaction to measles (rubeola) vaccine in patients hypersensitive to egg protein. J Pediatr. 1983;102:196-199 (Pubitemid 13194697)